Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica
Nanox appoints SOLME as Nanox.ARC distributor in Costa Rica, deepening its Latin American reach pending local regulatory registration.
Rhea-AI Summary
Nanox (NNOX) signed a distribution agreement with Costa Rica-based SOLME RC, S.A. to market and support the Nanox.ARC imaging system in Costa Rica. SOLME, a registered supplier to the national healthcare purchaser CCSS, will handle marketing, distribution, installation, training and ongoing technical support for Nanox.ARC and related services nationwide. Commercialization will proceed after Costa Rica’s regulatory registration process, which includes an initial six-month proof-of-concept device registration period before full registration. This is Nanox’s third Latin American market entry in 2026, following Argentina and Peru.
Positive
- None.
Negative
- None.
Key Figures
- POC registration period
- Six months
- Initial Costa Rica device registration before full registration
- Latin American market expansion
- 3rd market
- Third Latin American market this year, following Argentina and Peru
Historical Context
-
U.S. subsidiary added a regional partner to expand Nanox.ARC deployment
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
digital tomosynthesis technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement with SOLME RC, SA Marks the third Latin American market this year
PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (NASDAQ: NNOX) ("Nanox"), a leader in innovative medical imaging technology, today announced a distribution agreement with SOLME RC, S.A. (“SOLME”), a Costa Rica-based medical equipment distributor serving public and private healthcare institutions nationwide, to market and support the Nanox.ARC in Costa Rica.
Nanox.ARC is a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging.
Costa Rica’s healthcare system is anchored by the Caja Costarricense de Seguro Social (CCSS), which serves as the country’s principal purchaser and provider of hospital services. SOLME is a registered CCSS supplier for the equipment lines it represents.
Under the terms of the agreement, SOLME will serve as Nanox’s distributor for the Nanox.ARC and related services in Costa Rica, overseeing marketing, distribution, installation, training and ongoing technical support.
Commercialization in Costa Rica will follow the applicable regulatory registration process, which includes an initial six-month POC device registration period before full registration can be completed.
"Costa Rica is our third Latin American market this year, following Argentina and Peru," said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. "Our strategy in the region centers on partners with existing access to national healthcare purchasers, and SOLME’s established supplier relationships in Costa Rica directly fit that model."
"We are proud to partner with Nanox and bring the Nanox.ARC to healthcare providers throughout Costa Rica," said Carlos Peraza, General Manager of SOLME RC S.A. "Our experience supporting healthcare institutions across the country, combined with our established service and support capabilities, positions us well to support the deployment of Nanox solutions and help expand access to imaging services."
Founded in 2012, SOLME serves public and private healthcare institutions throughout Costa Rica, distributing medical equipment, replacement parts, consumables and radiation protection products to hospitals and clinics nationwide. The company is authorized by Costa Rica's Ministry of Health and Ministry of Finance to import and distribute medical equipment, and provides regulatory support, installation, training, technical service, and customer support.”
The agreement further strengthens Nanox's growing commercial presence in Latin America as the company continues to collaborate with regional partners to expand access to medical imaging and support healthcare providers in delivering care to more patients.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
